Jantunen I T, Kataja V V, Muhonen T T, Parviainen T
Department of Radiotherapy and Oncology, Central Hospital of Central Finland, Jyväskylä, Finland.
Cancer Chemother Pharmacol. 1996;37(5):502-4. doi: 10.1007/s002800050420.
Commercially available serotonin-type 3 (5-HT3) receptor antagonists (ondansetron, granisetron, and tropisetron) have shown no clinically significant adverse effects on the cardiovascular system. In the dose-ranging evaluation of dolasetron, computer-generated ECGs revealed clinically asymptomatic prolongations of ECG intervals. We performed a clinical trial in which the possible changes in ECG intervals following a single 3-mg i.v. injection of granisetron and an injection of either doxorubicin or epirubicin were registered using computerized ECG analysis in cancer patients. A total of 30 patients who were designated to receive 3 mg granisetron i.v. for the prophylaxis of emesis induced by doxorubicin or epirubicin were entered into the study. Computer-generated ECG tracings were obtained before treatment, following the injection of 3mg granisetron, and immediately after doxorubicin or epirubicin injection. The mean PR interval duration increased from 160 to 166 ms after granisetron infusion (P=0.02). Doxorubicin and epirubicin did not potentiate this change. There was no statistically significant change in cardiac rhythm, QRS duration, or QTc intervals. The observed minor changes in the PR time following i.v. injection of granisetron do not seem to be of clinical relevance.
市售的5-羟色胺3（5-HT3）受体拮抗剂（昂丹司琼、格拉司琼和托烷司琼）对心血管系统未显示出具有临床意义的不良反应。在多潘立酮的剂量范围评估中，计算机生成的心电图显示心电图间期出现临床上无症状的延长。我们进行了一项临床试验，使用计算机化心电图分析记录癌症患者单次静脉注射3毫克格拉司琼以及注射阿霉素或表柔比星后心电图间期可能发生的变化。共有30名被指定接受静脉注射3毫克格拉司琼以预防阿霉素或表柔比星引起的呕吐的患者进入该研究。在治疗前、注射3毫克格拉司琼后以及阿霉素或表柔比星注射后立即获取计算机生成的心电图描记图。格拉司琼输注后，平均PR间期从160毫秒增加到166毫秒（P = 0.02）。阿霉素和表柔比星并未增强这种变化。心律、QRS时限或QTc间期无统计学显著变化。静脉注射格拉司琼后观察到的PR间期的微小变化似乎与临床无关。
